Study Finds Cannabis Compounds May Help Reduce Fatty Liver Disease
Scientists at the Hebrew University of Jerusalem have found that compounds derived from cannabis may help reduce fat buildup in the liver, offering a possible new direction for treating fatty liver disease.
The findings, published in the British Journal of Pharmacology, show that two cannabinoids — Cannabidiol (CBD) and Cannabigerol (CBG) — improved liver health and metabolic function in experimental models.
Fatty liver affecting millions
The study focused on Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as fatty liver disease.
This condition is linked to obesity, insulin resistance and poor metabolic health. Health estimates suggest that about one in three adults globally may be affected, yet only a limited number of treatment options currently exist.
Compounds without a “high”
CBD is widely studied for its potential medical uses and does not produce intoxicating effects. CBG is less common but plays an important role in the cannabis plant as a precursor that leads to the formation of other cannabinoids, including CBD.
Both compounds differ from Tetrahydrocannabinol (THC), the psychoactive element in cannabis that causes the typical “high.” Their non-intoxicating nature makes them promising candidates for long-term therapeutic use.
Energy support for liver cells
Lead researcher Joseph Tam said the team discovered a new way these compounds may help the liver function better.
According to the study, CBD and CBG increase the production of phosphocreatine, a molecule that stores energy in cells. This acts like an energy reserve, helping liver cells continue working properly even when under stress from a high-fat diet.
Improving the liver’s clean-up process
The researchers also observed that the cannabinoids restored the activity of enzymes called cathepsins, which help break down fats and cellular waste.
With this system working more efficiently, the liver was better able to remove harmful lipids such as triglycerides and ceramides — substances linked to inflammation and metabolic disorders.
Among the two compounds, CBG showed stronger effects in some areas, including reducing body fat, lowering LDL cholesterol and improving insulin sensitivity.
Further research still needed
Despite the encouraging findings, the researchers noted that the study was conducted in controlled experimental conditions. More research, including clinical trials, will be necessary to determine whether these compounds can safely and effectively treat fatty liver disease in humans.
A separate review published in JAMA that analyzed over 2,500 studies on medical cannabis also highlighted the gap between public perception and the available scientific evidence.
Experts recommend that individuals consult healthcare professionals before considering cannabinoid-based treatments.
Disclaimer: This article is for informational and educational purposes only. It summarizes scientific research in simplified language and should not be considered medical or professional advice.
